Aclaris Therap | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 1.777 M

Revenue: As of FY2025 Q2, the actual value is USD 1.777 M, beating the estimate of USD 1.287 M.

EPS: As of FY2025 Q2, the actual value is USD -0.13, beating the estimate of USD -0.1343.

Financial Results

Net Loss

• Net loss for the second quarter of 2025 was $15.4 million, compared to $11.0 million for the second quarter of 2024.
• Net loss for the six months ended June 30, 2025 was $30.5 million, compared to $27.9 million for the same period in 2024.

Revenue

• Total revenue for the second quarter of 2025 was $1.8 million, compared to $2.8 million for the second quarter of 2024.
• Total revenue for the six months ended June 30, 2025 was $3.2 million, compared to $5.2 million for the same period in 2024.

Research and Development Expenses

• R&D expenses were $11.4 million for the quarter ended June 30, 2025, compared to $8.8 million for the corresponding period in 2024.
• R&D expenses for the six months ended June 30, 2025 were $23.0 million, compared to $18.6 million for the same period in 2024.

General and Administrative Expenses

• G&A expenses were $5.4 million for the quarter ended June 30, 2025, compared to $4.8 million for the corresponding period in 2024.
• G&A expenses for the six months ended June 30, 2025 were $11.5 million, compared to $11.6 million for the same period in 2024.

Cash Flow

• Net cash used in operating activities for the six months ended June 30, 2025 was - $23.1 million, compared to - $33.1 million for the same period in 2024.

Outlook / Guidance

• Aclaris Therapeutics expects its cash, cash equivalents, and marketable securities to fund operations into the second half of 2028.
• The company is exploring additional non-dilutive opportunities to extend its cash runway further.
• Aclaris plans to report top line results from its Phase 2 trial of bosakitug in AD in the second half of 2026 and from its Phase 1a/1b program of ATI-052 in early 2026 and the second half of 2026.